Hers vs Midi Health

Hers has an open FDA warning letter dated September 9, 2025. Midi Health has none. Midi Health lists its visit fee, and the medication is billed separately, so it has no all-in monthly price to set against another seller's. Hers starts at $199 a month for compounded semaglutide injection.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hers / Midi Health

Hers logo

Hers

6.8/10

Midi Health logo

Midi Health

4.9/10

FDA warning letters
None on record
Pharmacy
  • Precision Compounding Pharmacytype not stated
Lowest standing price
$199/moCompounded semaglutide injection
No GLP-1 price published
States
All 50 states
All 50 states
Checked
Prices captured Record checked September 2026
Prices captured Record checked September 2026

Neither Hers nor Midi Health pays us. Links to them earn nothing. Scores: Hers 6.8, Midi Health 4.9. How we are paid

What the record shows

  1. 01

    Hers has an open FDA warning letter dated September 9, 2025. Midi Health has none.

  2. 02

    Hers names three pharmacies. Midi Health names Precision Compounding Pharmacy.

  3. 03

    Midi Health lists its visit fee, and the medication is billed separately, so it has no all-in monthly price to set against another seller's. Hers starts at $199 a month for compounded semaglutide injection.

  4. 04

    Only Hers lists a price for compounded semaglutide injection and brand-name tirzepatide pen.

  5. 05

    Hers states you can cancel at any time; Midi Health does not state its cancellation terms.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hers

Midi Health

Compounded semaglutide injection

$199/mo

$2,388 a year

Not sold or not priced
Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Price includes
Medication
Not stated
Billed separately
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Not stated
Minimum term
None
Not stated
Refunds
No refund guaranteed once the pharmacy has processed an order
Payments are non-refundable; an order may be canceled before shipment at Midi's discretion

Read off each seller’s own pages. Hers: September 28, 2026. Midi Health: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hers

6.8/10
  • Sells compounded semaglutide injection and brand-name tirzepatide pen, which Midi Health does not price
  • States you can cancel at any time
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching

The case for Midi Health

4.9/10
  • No FDA warning letter on record
  • Publishes no GLP-1 price

Scores

Hers 6.8 · Midi Health 4.9 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
5.0

User Experience15%

8.0A
vs
B
2.5

Trust & Safety15%

7.0A
vs
B
6.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

3.0A
vs
B
5.0

The score is the same formula for every seller. Payment does not enter it. Method

Hers vs Midi Health: questions

Hers has an open FDA warning letter dated September 9, 2025. Midi Health has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Hers names three pharmacies. Midi Health names Precision Compounding Pharmacy.
Hers states you can cancel at any time; refunds: no refund guaranteed once the pharmacy has processed an order. Midi Health does not state its cancellation terms.
Neither Hers nor Midi Health pays us. Links to them earn nothing. Scores: Hers 6.8, Midi Health 4.9.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks